We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Kodiak Sciences Inc is is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. Kodiak Sciences Inc is is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases.
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results PR Newswire PALO ALTO, Calif., March 28, 2024 Three clinical programs present...
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 PR Newswire PALO ALTO, Calif., March 26, 2024 PALO ALTO, Calif...
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting PR Newswire PALO ALTO...
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire PALO ALTO, Calif., Jan. 4, 2024 PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc...
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire PALO ALTO, Calif., Nov. 21, 2023 PALO ALTO, Calif., Nov. 21, 2023 /PRNewswire/ -- Kodiak Sciences Inc...
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif., Nov. 14, 2023 PALO ALTO, Calif., Nov. 14, 2023 /PRNewswire/ -- Kodiak...
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a...
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.19 | -5.47550432277 | 3.47 | 3.56 | 3.17 | 404655 | 3.34110551 | CS |
4 | -2.11 | -39.146567718 | 5.39 | 5.39 | 3.17 | 645556 | 4.06102253 | CS |
12 | -1.07 | -24.5977011494 | 4.35 | 7.77 | 3.17 | 863000 | 5.33028371 | CS |
26 | 1.89 | 135.971223022 | 1.39 | 7.77 | 1.37 | 939286 | 3.85459283 | CS |
52 | -1.32 | -28.6956521739 | 4.6 | 9.8 | 1.37 | 903326 | 4.15960279 | CS |
156 | -118.36 | -97.3035185794 | 121.64 | 131.97 | 1.37 | 703134 | 15.87492375 | CS |
260 | -4.08 | -55.4347826087 | 7.36 | 171.21 | 1.37 | 558029 | 28.79772112 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions